M
Maximilian Mehdorn
Researcher at University of Kiel
Publications - 51
Citations - 4018
Maximilian Mehdorn is an academic researcher from University of Kiel. The author has contributed to research in topics: Parkinson's disease & Glasgow Outcome Scale. The author has an hindex of 23, co-authored 51 publications receiving 3445 citations.
Papers
More filters
Journal ArticleDOI
Neurostimulation for Parkinson's Disease with Early Motor Complications
W. M. M. Schuepbach,Jörn Rau,Karina Knudsen,Jens Volkmann,Paul Krack,Lars Timmermann,Thomas D. Hälbig,Helke Hesekamp,S. M. Navarro,Niklaus Meier,Daniela Falk,Maximilian Mehdorn,S. Paschen,Mohammad Maarouf,Michael T. Barbe,Gereon R. Fink,Andreas Kupsch,Doreen Gruber,G.-H. Schneider,Eric Seigneuret,Andrea Kistner,Patrick Chaynes,Fabienne Ory-Magne,C. Brefel Courbon,Jan Vesper,Alfons Schnitzler,Lars Wojtecki,Jean-Luc Houeto,Benoit Bataille,David Maltête,P. Damier,Sylvie Raoul,F. Sixel-Doering,D. Hellwig,Alireza Gharabaghi,Rejko Krüger,M. O. Pinsker,Florian Amtage,J. Regis,Tatiana Witjas,Stéphane Thobois,Patrick Mertens,Manja Kloss,Andreas Hartmann,Wolfgang H. Oertel,Bart Post,Hans Speelman,Yves Agid,Carmen Schade-Brittinger,Günther Deuschl +49 more
TL;DR: Subthalamic stimulation was superior to medical therapy in patients with Parkinson's disease and early motor complications and time with good mobility and no dyskinesia.
Journal ArticleDOI
NovoTTF-100A versus physician’s choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp,Eric T. Wong,Andrew A. Kanner,David M. Steinberg,Herbert H. Engelhard,Volkmar Heidecke,Eilon D. Kirson,Sophie Taillibert,Frank Liebermann,Vladimír Dbalý,Zvi Ram,J. Lee Villano,Nikolai G. Rainov,Uri Weinberg,David Schiff,Lara Kunschner,Jeffrey J. Raizer,Jérôme Honnorat,Andrew E. Sloan,Mark G. Malkin,Joseph Landolfi,F. Payer,Maximilian Mehdorn,Robert J. Weil,Susan C. Pannullo,Manfred Westphal,Martin Smrčka,Lawrence S. Chin,Herwig Kostron,Silvia Hofer,Jeffrey N. Bruce,Rees Cosgrove,Nina Paleologous,Yoram Palti,Philip H. Gutin +34 more
TL;DR: No improvement in overall survival was demonstrated, however efficacy and activity with this chemotherapy-free treatment device appears comparable to chemotherapy regimens that are commonly used for recurrent glioblastoma.
Journal ArticleDOI
Poor drug distribution as a possible explanation for the results of the PRECISE trial.
John H. Sampson,Gary E. Archer,Christoph Pedain,Eva Wembacher-Schröder,Manfred Westphal,Sandeep Kunwar,Michael A. Vogelbaum,April Coan,James E. Herndon,Raghu Raghavan,Martin Brady,David A. Reardon,Allan H. Friedman,Henry S. Friedman,M. Inmaculada Rodríguez-Ponce,Susan M. Chang,Stephan Mittermeyer,Davi Croteau,Raj K. Puri,James M. Markert,Michael D. Prados,Thomas C. Chen,Adam N. Mamelak,Timothy F. Cloughesy,John S. Yu,Kevin O. Lillehei,Joseph M. Piepmeier,Edward Pan,Frank D. Vrionis,H. Lee Moffitt,Jeffrey J. Olson,James P. Chandler,Nina Paleologos,Richard W. Byrne,Maciej S. Lesniak,Jon D. Weingart,Peter McL. Black,Tom Mikkelsen,Joon H. Uhm,Richard D. Bucholz,Lauren E. Abrey,Theodore H. Schwartz,Jeffrey N. Bruce,Anthony L. Asher,Stephen B. Tatter,Gene Barnett,Antonio E. Chiocca,Johnny B. Delashaw,Kevin Judy,Sunil J. Patel,Bruce Frankel,Frederick F. Lang,Pamela New,Karen Fink,Randy L. Jensen,Mark E. Shaffrey,Lynne P. Taylor,Warren Boling,Behnam Badie,Abhijit Guha,Vivek Mehta,Mark G. Hamilton,David D. Eisenstat,Farhad Pirouzmand,David R. Macdonald,Rolando F. Del Maestro,Daryl R. Fourney,Maximilian Mehdorn,Roland Goldbrunner,Gabriele Schackert,Andreas Unterberg,Zvi Ram,Zvi R. Cohen,Zvi H. Rappaport,Jan Jacob Mooij,John G. Wolbers,Peter C. Warnke,Varnavas Papanastassiou +77 more
TL;DR: Routine use of software algorithms and alternative catheter designs and infusion parameters may improve the efficacy of drugs delivered by CED, which may be severely constrained by ineffective delivery in many patients.
Journal ArticleDOI
Inhibition of TGF-beta2 with AP 12009 in recurrent malignant gliomas: from preclinical to phase I/II studies.
Peter Hau,Piotr Jachimczak,Reimar Schlingensiepen,Frank J. Schulmeyer,Tanya Jauch,Andreas Steinbrecher,Alexander Brawanski,Martin Proescholdt,J. Schlaier,Johanna Buchroithner,Josef Pichler,Gabriele Wurm,Maximilian Mehdorn,Rainer Strege,Gerhard Schuierer,Victoria Villarrubia,Franz A. Fellner,Olav Jansen,Thorsten Straube,Virinder Nohria,Michael Goldbrunner,Mechthild Kunst,S. Schmaus,Gerhard Stauder,Ulrich Bogdahn,Karl-Hermann Schlingensiepen +25 more
TL;DR: Results implicate targeted TGF-beta2-suppression using AP 12009 as a promising novel approach for malignant gliomas and other highly aggressive, T GF-beta-2-overexpressing tumors.
Journal ArticleDOI
Five-aminolevulinic acid for fluorescence-guided resection of recurrent malignant gliomas: a phase ii study.
Arya Nabavi,Holger Thurm,Basilios Zountsas,Thorsten Pietsch,Heinrich Lanfermann,Uwe Pichlmeier,Maximilian Mehdorn +6 more
TL;DR: 5-ALA fluorescence has a high predictive value for the detection of tumor in recurrent gliomas and is an effective surgical adjunct in the surgery of recurrent malignant glioma, according to prior treatment modalities.